Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL COLD AND SINUS vs AFRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
Temporary relief of sinus congestion and pressure,Temporary relief of nasal congestion,Temporary reduction of fever,Relief of minor aches and pains associated with the common cold or flu
Temporary relief of nasal congestion due to colds, hay fever, or other upper respiratory allergies.
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
Ibuprofen: 2-4 hours (terminal; rapid elimination, no accumulation with intermittent use). Pseudoephedrine: 4-8 hours (terminal; prolonged in alkaline urine, up to 16 hours at p H 8).
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Pseudoephedrine is partially metabolized in the liver by N-demethylation.
Primarily hepatic metabolism via oxidative deamination and glucuronidation; the major enzyme involved is monoamine oxidase (MAO).
Renal excretion of unchanged drug and metabolites: ibuprofen ~45-60% (primarily as conjugated metabolites, <10% unchanged), pseudoephedrine ~70-90% unchanged. Biliary/fecal elimination accounts for <10% for both components.
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
Ibuprofen: ~99% primarily to albumin. Pseudoephedrine: negligible (<10% bound to plasma proteins).
80–90% bound to serum albumin and alpha-1-acid glycoprotein.
Ibuprofen: 0.1-0.2 L/kg (low Vd, indicating limited tissue distribution). Pseudoephedrine: 2.5-3.5 L/kg (high Vd, extensive tissue distribution including CNS).
4.0–5.0 L/kg. Indicates extensive tissue distribution, with concentrations exceeding plasma levels in lung, liver, kidney, and brain.
Oral: ibuprofen ~80-100% (rapidly absorbed, no significant first-pass). Pseudoephedrine ~100% (well absorbed, minimal first-pass metabolism).
Oral: 40–50% (first-pass metabolism). Intranasal: 70–80% (systemic absorption variable). Intravenous: 100%.
GFR 30-89 m L/min: Use lowest effective dose for shortest duration; monitor renal function. GFR <30 m L/min or dialysis: Contraindicated.
Cr Cl 30-50 m L/min: prolong interval to every 18-24 hours; Cr Cl <30 m L/min: avoid use.
Child-Pugh Class A: No adjustment; use with caution. Child-Pugh Class B or C: Avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: avoid use.
Children <12 years: Do not use. Children ≥12 years: Same as adult dosing; 1-2 tablets every 4-6 hours as needed; maximum 6 tablets in 24 hours.
Children 6-12 years: 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; maximum 1 tablet per day. Children <6 years: not recommended.
Use lowest effective dose for shortest duration; avoid chronic use. Reduce initial dose to 1 tablet every 6-8 hours due to increased risk of renal impairment, GI bleeding, and cardiovascular events.
Start with 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; monitor for CNS effects, anticholinergic side effects, and hypertension.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
None.
Cardiovascular thrombotic events, gastrointestinal bleeding/ulceration/perforation, hypertension, renal toxicity, serious skin reactions, anaphylactoid reactions, exacerbation of asthma, and drug interactions including with ACE inhibitors, diuretics, and lithium.
Hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, increased intraocular pressure, prostatic hyperplasia; use caution in elderly patients; do not exceed recommended dosage.
Hypersensitivity to ibuprofen, aspirin, or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; patients with severe hypertension or coronary artery disease; patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs; concurrent use of other sympathomimetics; in the setting of CABG surgery.
Hypersensitivity to any component; concurrent use or recent use (within 14 days) of MAO inhibitors; severe hypertension or coronary artery disease.
Take with food or milk to reduce gastrointestinal irritation. Avoid alcohol consumption as it increases the risk of NSAID-related gastric ulcers and bleeding. High-sodium foods may exacerbate hypertension in patients sensitive to the pressor effects of pseudoephedrine.
Avoid excessive caffeine intake as it may increase stimulant effects. No significant food interactions known.
First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.62) for any malformation and 1.86 (95% CI 1.32-2.62) for cardiac malformations. Second trimester: Risk of oligohydramnios and premature closure of ductus arteriosus after 20 weeks. Third trimester: Avoid after 30 weeks due to risk of premature ductus arteriosus closure and oligohydramnios; after 32 weeks, increased risk of necrotizing enterocolitis, intracranial hemorrhage, and renal impairment in neonate (renal agenesis/dysgenesis). Pseudoephedrine: First trimester – possible increased risk of gastroschisis (odds ratio 1.8, 95% CI 1.0-3.2) and small intestinal atresia. Second and third trimesters: potential uteroplacental vasoconstriction leading to fetal hypoxia; risk of prematurity and low birth weight.
Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsistent. Second and third trimesters: Avoid due to risk of uterine vasoconstriction and potential fetal hypoxia, especially near term. Overall, FDA Pregnancy Category C.
Ibuprofen: M/P ratio 0.005–0.006; low transfer into breast milk; AAP compatible; theoretical risk of platelet dysfunction in neonate. Pseudoephedrine: M/P ratio 2.6–3.5 (concentrated in milk); estimated infant dose 4.3% of maternal weight-adjusted dose; may cause irritability and sleep disturbances in infant; may reduce milk production by up to 24%. Caution advised; avoid in lactation if possible.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio approximately 2.6–3.5). Use with caution as it can reduce milk production and may cause irritability in the infant. A single dose is likely safe, but chronic use is not recommended.
Ibuprofen: No dose adjustment required; however, use lowest effective dose and shortest duration; avoid after 30 weeks gestation. Pseudoephedrine: No specific dose adjustment recommended based on pharmacokinetic changes, but use with caution due to vasoconstrictive effects; reduced efficacy may be observed due to increased plasma volume and renal clearance.
No specific dose adjustments are established for pregnancy. However, due to increased plasma volume and renal clearance, the duration of action may be shorter. Use the lowest effective dose for the shortest duration, typically 60 mg every 4–6 hours (max 240 mg/day).
Advil Cold and Sinus is a fixed-dose combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen inhibits COX-1/2, reducing prostaglandin synthesis, while pseudoephedrine is an α-adrenergic agonist causing vasoconstriction in nasal mucosa. Use cautiously in patients with hypertension, cardiovascular disease, or renal impairment due to pseudoephedrine's pressor effects and ibuprofen's potential to reduce renal blood flow and antagonize antihypertensives. Avoid in patients with severe coronary artery disease, uncontrolled hypertension, or concurrent MAOI use. Max duration: 3 days for sinus symptoms, 5 days for pain. Monitor for NSAID-induced GI bleeding, especially in elderly or those on anticoagulants/aspirin.
AFRINOL contains oxymetazoline, an imidazoline sympathomimetic with alpha-adrenergic agonist activity. It causes vasoconstriction in nasal mucosa. Limit use to 3 days to avoid rhinitis medicamentosa. Avoid in patients with narrow-angle glaucoma, severe hypertension, or MAOI use. Onset is within minutes, duration up to 12 hours.
Do not take more than directed; do not exceed 6 caplets in 24 hours.,Avoid use with other products containing ibuprofen or other NSAIDs, including aspirin, to prevent overdose and serious side effects.,Discontinue use and seek medical attention if symptoms worsen, persist >3 days for sinus or >5 days for pain, or if new symptoms occur.,Take with food or milk to reduce stomach upset; avoid alcohol to lower risk of GI bleeding.,If you have high blood pressure, heart disease, thyroid disease, diabetes, or difficulty urinating due to prostate enlargement, consult a doctor before use.,Do not use if you are taking a prescription monoamine oxidase inhibitor (MAOI) or for 2 weeks after stopping an MAOI drug.,Pregnant or breastfeeding women should not use this product; ibuprofen is contraindicated in third trimester due to risk of premature closure of ductus arteriosus.,Store at room temperature away from moisture and heat.
Do not use for more than 3 consecutive days to avoid rebound congestion.,Do not share the bottle with others to prevent infection.,Do not exceed recommended dosage; use only 2-3 sprays per nostril every 10-12 hours as directed.,Avoid using if you have high blood pressure, heart disease, or glaucoma without consulting a doctor.,Consult a doctor if symptoms persist beyond 3 days or if you experience severe side effects like headache, rapid heartbeat, or dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL COLD AND SINUS vs AFRINOL, answered by our medical review team.
ADVIL COLD AND SINUS is a NSAID/Decongestant Combination that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.. AFRINOL is a Decongestant that works by Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL COLD AND SINUS and AFRINOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL COLD AND SINUS is: 1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.. The standard adult dose of AFRINOL is: Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL COLD AND SINUS and AFRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL COLD AND SINUS is classified as Category C. First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.. AFRINOL is classified as Category C. Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsist. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.